- Revance to Showcase Data from Phase 3 ASPEN-1 Clinical Trial Evaluating Efficacy, Duration of Effect and Safety of DaxibotulinumtoxinA for Injection for Cervical Dystonia at International Parkinson and Movement Disorder Society Virtual Congress 2021
- Revance Presents Data on the RHA® Collection of Dermal Fillers at the 2021 Virtual Skin of Color Update Meeting
- Revance to Participate in the Wells Fargo Securities Healthcare Conference
- Revance Announces Publication of Results on Static Glabellar Lines With Repeated Treatment of DaxibotulinumtoxinA for Injection From the SAKURA Clinical Program in Dermatologic Surgery
- Revance Reports Second Quarter 2021 Financial Results, Provides Corporate Update
- Revance to Release Second Quarter 2021 Financial Results on Thursday, August 5, 2021
Revance Therapeutics Inc (RTI:STU) closed at 21.80, 13.54% above the 52 week low of 19.20 set on Dec 03, 2020.
19.20Dec 03 202027.80Jul 09 2021
Markit short selling activity
|Market cap||1.90bn USD|
|EPS (TTM)||-4.72 |
Data delayed at least 15 minutes, as of Sep 16 2021.